No Data
No Data
Express News | Eloxx Pharmaceuticals Inc: Under Terms of Deal, Co Is Eligible for Additional Development, Regulatory, Sales Milestones of up to $470 Mln
Express News | Eloxx Pharmaceuticals Inc: Zkn-013 Has Been Exclusively Licensed to Almirall, S.A. Who Has Global Rights to Develop and Commercialize Zkn-013
Press Release: Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Alport Syndrome Pipeline Insight 2024, Featuring Eloxx Pharmaceuticals, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics and Reata Pharmaceuticals
Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative
Almirall and Eloxx Pharmaceuticals Enter Into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Unlock the Full List